Linguistic Foundations for L2 Pronunciation Teaching

In this session I present a course I am proposing (and will pilot in short form this summer in Mongolia) entitled “Linguistic Foundations for L2 Pronunciation Teaching.” This course is designed to provide language-teaching majors with key linguistic foundation in phonetics and phonology to be able to analyze the linguistic source of pronunciation errors accurately and provide students with clear explanations and effective, individualized coaching. For non-native speakers of the language they will be teaching, the course is designed as well to strengthen their own pronunciation. A major component of the course will be hands-on working with L2 speakers, chosen by the student. Course objectives are as follows: Describe and accurately pronounce sounds from a variety of languages Transcribe sounds and words using the International Phonetic Alphabet Analyze data from a variety of languages to determine basic relationships: phonemic and allophonic relationships, and phonotactic patterns in syllables and words Describe the phonetic and phonological patterns of English, as well as other major languages as may suit the needs of the class Identify likely pronunciation issues between a given L1 and L2, based on differences in phonetic and phonological patterns. Be able to identify the source of pronunciation errors in the speech of actual L2 learners and propose linguistically-based pedagogical responses Employ a variety of linguistically-based strategies to help actual L2 learners master difficult sounds and sound patterns, in hands-on teaching. The inspiration for this course arose from grateful comments from students in my pronunciation classes, requests from non-native-speaking TESOL majors for help with their own pronunciation, comments from TESOL observers of my classes, and my observations of pronunciation textbooks and seminars designed for language teachers. A course such as this offered to language-teaching programs can raise the profile and perceived value of linguistics on a campus, along with providing key linguistic preparation to students preparing for careers in language teaching. To access PowerPoint slides for this presentation: Click the Download button on the upper right-hand side of the page

Use of emerging technologies to help measure fjordic biodiversity and blue carbon: mini-manned submarines and autonomous underwater vehicle swarms

Meaningful protection of global oceans lags far behind that of land and has taken little consideration of climate mitigation potential to date (such as through assessment of blue carbon stocks and change). With the new emphasis on synergistic approaches to the identification and conservation of both carbon- and species- rich habitats, we need much better knowledge of the geography and status of blue carbon habitats beyond coastal wetlands. In subpolar and polar regions, some blue carbon habitats are still emerging and work as negative (mitigating) feedback on climate change, yet remain unprotected despite strong evidence of threat overlap. Scientific research expeditions are gradually increasing our understanding, but appropriate vessels are a limiting factor due to high costs and carbon footprints. Even when available such vessels cannot access all areas (e.g., remote fjords with sills) and may struggle to measure certain aspects of habitats (e.g., steep or vertical surfaces). New technologies and opportunities have advanced to aid some of these problems, and here, two of them are considered, mini-manned submersibles and autonomous underwater vehicles. These two platforms have both become much more available and affordable (through novel partnerships) while also being much more scientifically capable. This technology has the potential to reduce the carbon footprint of science and particularly aid in assessing biology and environment status and change on steep sides, such as fjord walls

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

To understand neurological complications of COVID-19 better both acutely and for recovery, we measured markers of brain injury, inflammatory mediators, and autoantibodies in 203 hospitalised participants; 111 with acute sera (1–11 days post-admission) and 92 convalescent sera (56 with COVID-19-associated neurological diagnoses). Here we show that compared to 60 uninfected controls, tTau, GFAP, NfL, and UCH-L1 are increased with COVID-19 infection at acute timepoints and NfL and GFAP are significantly higher in participants with neurological complications. Inflammatory mediators (IL-6, IL-12p40, HGF, M-CSF, CCL2, and IL-1RA) are associated with both altered consciousness and markers of brain injury. Autoantibodies are more common in COVID-19 than controls and some (including against MYL7, UCH-L1, and GRIN3B) are more frequent with altered consciousness. Additionally, convalescent participants with neurological complications show elevated GFAP and NfL, unrelated to attenuated systemic inflammatory mediators and to autoantibody responses. Overall, neurological complications of COVID-19 are associated with evidence of neuroglial injury in both acute and late disease and these correlate with dysregulated innate and adaptive immune responses acutely

Use of emerging technologies to help measure fjordic biodiversity and blue carbon: mini-manned submarines and autonomous underwater vehicle swarms

Meaningful protection of global oceans lags far behind that of land and has taken little consideration of climate mitigation potential to date (such as through assessment of blue carbon stocks and change). With the new emphasis on synergistic approaches to the identification and conservation of both carbon- and species- rich habitats, we need much better knowledge of the geography and status of blue carbon habitats beyond coastal wetlands. In subpolar and polar regions, some blue carbon habitats are still emerging and work as negative (mitigating) feedback on climate change, yet remain unprotected despite strong evidence of threat overlap. Scientific research expeditions are gradually increasing our understanding, but appropriate vessels are a limiting factor due to high costs and carbon footprints. Even when available such vessels cannot access all areas (e.g., remote fjords with sills) and may struggle to measure certain aspects of habitats (e.g., steep or vertical surfaces). New technologies and opportunities have advanced to aid some of these problems, and here, two of them are considered, mini-manned submersibles and autonomous underwater vehicles. These two platforms have both become much more available and affordable (through novel partnerships) while also being much more scientifically capable. This technology has the potential to reduce the carbon footprint of science and particularly aid in assessing biology and environment status and change on steep sides, such as fjord walls

Six-month outcomes following an emergency hospital admission for older adults with co-morbid mental health problems indicate complexity of care needs

BACKGROUND: two-thirds of older patients admitted as an emergency to a general hospital have co-existing mental health problems including delirium, dementia and depression. This study describes the outcomes of older adults with co-morbid mental health problems after an acute hospital admission. METHODS: a follow-up study of 250 patients aged over 70 admitted to 1 of 12 wards (geriatric, medical or orthopaedic) of an English acute general hospital with a co-morbid mental health problem and followed up at 180 days. RESULTS: twenty-seven per cent did not return to their original place of residence after the hospital admission. After 180 days 31% had died, 42% had been readmitted and 24% of community residents had moved to a care home. Only 31% survived without being readmitted or moving to a care home. However, 16% spent >170 of the 180 days at home. Significant predictors for poor outcomes were co-morbidity, nutrition, cognitive function, reduction in activities of daily living ability prior to admission, behavioural and psychiatric problems and depression. Only 42% of survivors recovered to their pre-acute illness level of function. Clinically significant behavioural and psychiatric symptoms were present at follow-up in 71% of survivors with baseline cognitive impairment, and new symptoms developed frequently in this group. CONCLUSIONS: the variable, but often adverse, outcomes in this group implies a wide range of health and social care needs. Community and acute services to meet these needs should be anticipated and provided for

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811)

BACKGROUND: We conducted a 2-part study to evaluate the incorporation of veliparib, a PARP inhibitor, into chemoradiotherapy (CRT) for stage III non-small-cell lung cancer. PATIENTS AND METHODS: In the phase I part, patients were treated successively at 3 dose levels of veliparib (40, 80, and 120 mg) twice daily during CRT. In the phase II part, patients were randomized to receive veliparib or placebo during thoracic radiotherapy with concurrent weekly carboplatin and paclitaxel, followed by 2 cycles of consolidation carboplatin and paclitaxel with veliparib or placebo. The study was prematurely discontinued owing to the emergence of adjuvant immunotherapy as standard of care. RESULTS: Of 21 patients enrolled in phase I, 2 patients developed dose-limiting toxicities (DLTs): 1 grade 3 esophagitis with dysphagia (at 40 mg) and 1 grade 3 esophagitis with dehydration (at 80 mg). No DLTs were seen at veliparib dose of 120 mg twice daily, which was selected for the phase II part that enrolled 31 eligible patients. Progression-free survival (PFS) was not different between the 2 arms (P = .20). For the veliparib and placebo arms, response rates were 56% and 69%, PFS at 1 year 47% and 46%, and overall survival at 1 year 89% and 54%, respectively. CONCLUSION: Veliparib with CRT was feasible and well tolerated. Efficacy could not accurately be determined because of early study closure. Nonetheless, there is enthusiasm for the evaluation of PARP inhibitors in lung cancer as predictive biomarkers are being developed and combinations with immunotherapy are attractive

The Origin and in Vivo Significance of Murine and Human Culture-Expanded Endothelial Progenitor Cells

In adults highly purified populations of early hematopoietic progenitors or cells derived from ex vivo expanded unmobilized human peripheral blood mononuclear cells contribute to new blood vessel formation. However, the source of these culture-expanded endothelial progenitor cells (CE-EPCs) remains controversial. We demonstrate that ex vivo expansion of unmobilized human peripheral blood generated CE-EPCs with similar numbers, kinetics, and antigen expression profile as compared to plating unfractionated CD34(+)/lin(−)-enriched bone marrow mononuclear cells. Both CE-EPC populations uniformly co-expressed myeloid and endothelial markers, suggesting that peripheral blood progenitor enumeration does not correlate with the numbers of early outgrowth CE-EPCs. Using purified myeloid subpopulations obtained from mice harboring the lacZ transgene driven by an endothelial-specific promoter, we showed that the immature myeloid lineage marker CD31(+) cells generated CE-EPCs with fourfold greater frequency than mature myeloid populations. Biphenotypic cells co-expressing myeloid/endothelial antigens were not detected in circulating human or murine peripheral blood or bone marrow but were associated with murine tumors. Unlike CE-EPCs, CD14(+) leukocytes admixed within tumors did not generate vWF-positive blood vessels during a similarly defined period of tumor growth, but some leukocytes up-regulated the endothelial marker VE-cadherin. Taken together, the data suggest that the local neovascular microenvironment may facilitate vasculogenesis by promoting endothelial differentiation and that CE-EPCs may accelerate such vasculogenesis